Long-term outcome of coronary balloon angioplasty in diabetic patients

International Journal of Cardiology

Volumn 76, Issue 1, 2000, Pages 7-16

  Przewlocki, Tadeusz ^a   Pieniazek, Piotr ^a   Ryniewicz, Wojciech ^a   Kostkiewicz, Magdalena ^a   Olszowska, Maria ^a   Podolec, Piotr ^a   Sedziwy, Ewa ^a   Tracz, Wieslawa ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angioplasty; Diabetes mellitus; Event free survival; Functional status; Restenosis; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033762605     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00365-X     Document Type: Article

References (62)

1. Acute myocardial infarction in diabetes mellitus
2. Diabetes and cardiovascular disease: the Framingham Study
3. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
4. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty
5. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
6. Cause of death in the NHLBI PTCA registry: results and considerations for evaluating long-term survival after coronary interventions
7. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged >65 years (report from the CASS Registry)
8. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting
9. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute
10. Recurrence after coronary angioplasty
11. Repeat coronary angioplasty for restenosis: results and predictors of follow up clinical events
12. Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis
13. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural and lesional factors related to long-term angiographic outcome
14. Can restenosis after coronary angioplasty be predicted from clinical variables?
15. Effect of prior coronary restenosis on the risk of subsequent restenosis after stent placement or directional atherectomy
16. Importance of stenosis morhology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty
17. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty
18. Predictive factors of restenosis after multivessel percutaneous transluminal coronary angioplasty
19. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus. A clue to the explanation of the results of the BARI study
20. Influences of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease
21. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation)
22. Coronary surgery and PTCA in diabetics with multivessel disease: can the BARI results be generalized
23. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients
24. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease
25. Guidelines for percutaneous transluminal angioplasty: a report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures
26. Grading of angina pectoris
27. Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settings
28. Long-term outcome following successful reopening of abrupt closure after coronary angioplasty
29. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty
30. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease
31. Diabetics have a significantly poorer eight year outcome after angioplasty
32. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996
33. The influence of diabetes on outcome of percutaneous coronary intervention: the NHLBI 1997-98 Dynamic Registry
34. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients
35. Multivessel balloon angioplasty should be abandoned in diabetic patients
36. The interventional cardiologist and the diabetic patient. Have we pushed the envelope too far or not far enough?
37. Potential mechanisms promoting restenosis in diabetic patients
38. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study
39. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus
40. Coronary stenting in the diabetic patients: early and follow-up results
41. Predictive factors of restenosis after coronary stent placement
42. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation
43. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement
44. Risk factors for progression of atherosclerosis six months after balloon angioplasty of coronary stenosis
45. Angiographic stenosis progression and coronary events in patients with 'stabilized' unstable angina
46. The influence of diabetes and hypertension on the results of coronary revascularization
47. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS)
48. Influence of diabetes and mammary artery grafting on survival after coronary bypass
49. Predictors of long-term survival in patients with multivessel coronary artery disease undergoing percutaneous transluminal coronary angioplasty
50. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics
51. Does abciximab improve outcome following angioplasty in diabetics? Long-term follow up results from the EPIC Study
52. Predictors of late occlusion after angioplasty for unstable angina: 6 month angiographic follow-up of the RESTORE study
53. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin. Evidence for a complex interaction from a multicenter trial
54. Tirofiban - an overview of the phase III trials
55. Marked benefit in diabetic patients treated with stent and abciximab combination: 6 month outcome of the EPISTENT Trial
56. Catheter-based radiotherapy to inhibit restenosis after coronary stenting
57. Problem of angioplasty in diabetics
58. Outcomes and their predictors after PTCA in patients with type II diabetes mellitus
59. Intensive blood glucose control with sulphonyloureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
60. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
61. The United Kingdom Prospective Diabetes Study - everything you needed to know about diabetes but were afraid to ask?
62. Lipid-lowering trials in diabetes